Department of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China; Central Laboratory, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Central Laboratory, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Biomed Pharmacother. 2024 Aug;177:116943. doi: 10.1016/j.biopha.2024.116943. Epub 2024 Jun 14.
The immunosuppressive microenvironment is a vital factor for the hepatocellular carcinoma (HCC) progression. However, effective treatment is lacking at current. Shenlian decoction (SLD) is a registered herbal therapy for the HCC treatment, but the underlying mechanism of SLD remains largely elusive. Here, we aimed to explore the anti-tumor effect of SLD in the treatment of HCC. SLD was intragastrically given after the tumor initiation in β-catenin/C-Met or DEN and CCl induced HCC mouse model. The tumor growth levels were evaluated by liver weight and histological staining. The tumor-infiltrating immune cells were detected by immunological staining and flow cytometry. The mechanism of the SLD was detected by non-targeted proteomics and verified by a cell co-culture system. The result showed that SLD significantly attenuated HCC progression. SLD promoted macrophage infiltration and increased the M1/M2 macrophage ratio within the tumor tissues. Non-targeted proteomics showed the inhibition of complement C5/C5a signaling is the key mechanism of SLD. Immunological staining showed SLD inhibited C5/C5a expression and C5aR1 macrophage infiltration. The suggested mechanism was demonstrated by application of C5aR1 inhibitor, PMX-53 in mouse HCC model. Hepatoma cell-macrophage co-culture showed SLD targeted hepatoma cells and inhibited the supernatant-induced macrophage M2 polarization. SLD inhibited AMPK/p38 signaling which is an upstream mechanism of C5 transcription. In conclusion, we found SLD relieved immune-suppressive environment by inhibiting C5 expression. SLD could suppress the C5 secretion in hepatoma cells via inhibition of AMPK/p38 signaling. We suggested that SLD is a potential herbal therapy for the treatment of HCC by alleviating immune-suppressive status.
免疫抑制微环境是肝细胞癌 (HCC) 进展的重要因素。然而,目前缺乏有效的治疗方法。参莲汤 (SLD) 是一种用于治疗 HCC 的注册草药疗法,但 SLD 的潜在机制仍很大程度上难以捉摸。在这里,我们旨在探索 SLD 在治疗 HCC 中的抗肿瘤作用。在β-catenin/C-Met 或 DEN 和 CCl 诱导的 HCC 小鼠模型中,在肿瘤起始后通过胃内给予 SLD。通过肝重和组织学染色评估肿瘤生长水平。通过免疫染色和流式细胞术检测肿瘤浸润免疫细胞。通过非靶向蛋白质组学检测 SLD 的机制,并通过细胞共培养系统进行验证。结果表明,SLD 显著减弱了 HCC 的进展。SLD 促进了巨噬细胞浸润,并增加了肿瘤组织内的 M1/M2 巨噬细胞比例。非靶向蛋白质组学显示抑制补体 C5/C5a 信号是 SLD 的关键机制。免疫染色显示 SLD 抑制了 C5/C5a 的表达和 C5aR1 巨噬细胞浸润。通过在小鼠 HCC 模型中应用 C5aR1 抑制剂 PMX-53 验证了该建议机制。肝癌细胞-巨噬细胞共培养显示 SLD 靶向肝癌细胞并抑制上清液诱导的巨噬细胞 M2 极化。SLD 抑制了 AMPK/p38 信号通路,这是 C5 转录的上游机制。总之,我们发现 SLD 通过抑制 C5 的表达缓解了免疫抑制环境。SLD 可以通过抑制 AMPK/p38 信号通路来抑制肝癌细胞中 C5 的分泌。我们建议 SLD 通过缓解免疫抑制状态,是一种治疗 HCC 的潜在草药疗法。